The shared tumor-associated antigen cytochrome P450 1B1 is recognized by specific cytotoxic T cells

Blood

Volumn 102, Issue 9, 2003, Pages 3287-3294

  Maecker, Britta ^b   Sherr, David H ^b   Vonderheide, Robert H ^b   Von Bergwelt Baildon, Michael S ^b   Hirano, Naoto ^b   Anderson, Karen S ^b   Xia, Zhinan ^b   Butler, Marcus O ^b   Wucherpfennig, Kai W ^b   O'Hara, Carl ^b   Cole, Geoffrey ^b   Kwak, Silvia S ^b   Ramstedt, Urban ^b   Tomlinson, Andy J ^b   Chicz, Roman M ^b   Nadler, Lee M ^b   Schultze, Joachim L ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 1B1; EPITOPE; GAMMA INTERFERON; HLA A2 ANTIGEN; PLASMID DNA; TUMOR ANTIGEN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL CELL; ARTICLE; BREAST CARCINOMA; CANCER IMMUNOTHERAPY; COLON CARCINOMA; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; DNA VECTOR; DRUG TARGETING; FEMALE; FOLLICULAR LYMPHOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MELANOMA CELL; MOUSE; MULTIPLE MYELOMA; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; PROSTATE CANCER; TRANSGENIC MOUSE;

EID: 0142152431     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-05-1374     Document Type: Article

References (45)

1. Luch A, Coffing SL, Tang YM, et al. Stable expression of human cytochrome P450 1B1 in V79 Chinese hamster cells and metabolically catalyzed DNA adduct formation of dibenzo[a, l]-pyrene. Chem Res Toxicol. 1998;11:686-695.
2. Larsen MC, Angus WG, Brake PB, Eltom SE, Sukow KA, Jefcoate CR. Characterization of CYP1B1 and CYP1A1 expression in human mammary epithelial cells: role of the aryl hydrocarbon receptor in polycyclic aromatic hydrocarbon metabolism. Cancer Res, 1998;58:2366-2374.
3. Trombino AF, Near RI, Matulka RA, et al. Expression of the aryl hydrocarbon receptor/transcription factor (AhR) and AhR-regulated CYP1 gene transcripts in a rat model of mammary tumorigenesis. Breast Cancer Res Treat. 2000;63:117-131.
4. Murray GI, Taylor MC, McFadyen MC, et al. Tumor-specific expression of cytochrome P450 CYP1B1. Cancer Res. 1997;57:3026-3031.
5. Nadler LM, Schultze JL. From genomics to cancer vaccines: patient-tailored or universal vaccines? Curr Opin Mol Ther. 2002;4:572-576.
6. Brossart P, Heinrich KS, Stuhler G, et al. Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies. Blood. 1999;93:4309-4317.
7. + T effector cells by dendritic cells pulsed with protein or selected peptides. Cancer Res. 2000;60:4845-4849.
8. Andersen MH, Pedersen LO, Becker JC, Straten PT, Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein survivin in cancer patients. Cancer Res. 2001;61:869-872.
9. Schmidt SM, Schag K, Mueller MR, et al. Survivin is a shared tumor associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T-cells. Blood. 2003;102:571-576.
10. Vonderheide RH, Hahn WC, Schultze JL, Nadler LM. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity. 1999;10:673-679.
11. Vonderheide RH, Anderson KS, Hahn WC, Butler MO, Schultze JL, Nadler LM. Characterization of HLA-A3-restricted T cells reactive against the universal tumor antigen telomerase for widely applicable anti-cancer immunotherapy. Clin Cancer Res. 2001;7:3343-3348.
12. Gedde-Dahl TD, Eriksen JA, Thorsby E, Gaudernack G. T-cell responses against products of oncogenes: generation and characterization of human T-cell clones specific for p21 ras-derived synthetic peptides. Hum Immunol. 1992;33:266-274.
13. Theobald M, Biggs J, Dittmer D, Levine AJ, Sherman LA. Targeting p53 as a general tumor antigen. Proc Natl Acad Sci U S A. 1995;92:11993-11997.
14. McFadyen MC, Breeman S, Payne S, et al. Immunohistochemical localization of cytochrome P450 CYP1B1 in breast cancer with monoclonal antibodies specific for CYP1B1. J Histochem Cytochem. 1999;47:1457-1464.
15. Parker KC, Bednarek MA, Coligan JE. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol. 1994;152:163-175.
16. Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics. 1999;50:213-219.
17. Ruppert J, Sidney J, Celis E, Kubo RT, Grey HM, Sette A. Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules. Cell. 1993;74:929-937.
18. Tomlinson AJ, Hincapie M, Morris GE, Chicz RM. Global proteome analysis of a human gastric carcinoma. Electrophoresis. 2002;23:3233-3240.
19. Tomlinson AJ, Chicz RM. Microcapillary liquid chromatography/tandem mass spectrometry using alkaline pH mobile phases and positive ion detection. Rapid Commun Mass Spectrom. 2003;17:909-916.
20. von Bergwelt-Baildon MS, Vonderheide RH, Maecker B, et al. Human primary and memory cytotoxic T lymphocyte responses are efficiently induced by means of CD40-activated B cells as antigen-presenting cells: potential for clinical application. Blood. 2002;99:3319-3325.
21. Sutter TR, Tang YM, Hayes CL, et al. Complete cDNA sequence of a human dioxin-inducible mRNA identifies a new gene subfamily of cytochrome P450 that maps to chromosome 2. J Biol Chem. 1994;269:13092-13099.
22. Mackett M, Smith GL, Moss B. Vaccinia virus: a selectable eukaryotic cloning and expression vector. Biotechnology. 1992;24:495-499.
23. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med. 1994;179:1109-1118.
24. Vonderheide RH, Schultze JL, Anderson KS, et al. Equivalent induction of telomerase-specific cytotoxic T lymphocytes from tumor-bearing patients and healthy individuals. Cancer Res. 2001;61:8366-8370.
25. Vitiello A, Marchesini D, Furze J, Sherman LA, Chesnut RW. Analysis of the HLA-restricted influenza-specific cytotoxic T lymphocyte response in transgenic mice carrying a chimeric human-mouse class I major histocompatibility complex. J Exp Med. 1991;173:1007-1015.
26. Hedley ML, Curley J, Urban R. Microspheres containing plasmid-encoded antigens elicit cytotoxic T-cell responses. Nat Med. 1998;4:365-368.
27. McFadyen MC, Cruickshank ME, Miller ID, et al. Cytochrome P480 CYP1B1 over-expression in primary and metastatic ovarian cancer. Br J Cancer. 2001;85:242-246.
28. Hakkola J, Pasanen M, Pelkonen O, et al. Expression of CYP1B1 in human adult and fetal tissues and differential inducibility of CYP1B1 and CYP1A1 by Ah receptor ligands in human placenta and cultured cells. Carcinogenesis. 1997;18:391-397.
29. Baron JM, Zwadlo-Klarwasser G, Jugert F, et al. Cytochrome P450 1B1: a major P450 isoenzyme in human blood monocytes and macrophage subsets. Biochem Pharmacol. 1998;56:1105-1110.
30. Dassi C, Signorini S, Gerthoux P, Cazzaniga M, Brambilla P. Cytochrome P450 1B1 mRNA measured in blood mononuclear cells by quantitative reverse transcription-PCR. Clin Chem. 1998;44:2416-2421.
31. Rieder CR, Ramsden DB, Williams AC. Cytochrome P450 1B1 mRNA in the human central nervous system. Mol Pathol. 1998;51:138-142.
32. Muskhelishvili L, Thompson PA, Kusewitt DF, Wang C, Kadlubar FF. In situ hybridization and immunohistochemical analysis of cytochrome P450 1B1 expression in human normal tissues. J Histochem Cytochem. 2001;49:229-236.
33. Lill JR, Lazar AC, Corbo JA, et al. Attomole level sequencing of HLA restricted peptides by automated micro-capillary LC/MS/MS. Proceedings of the 49th Annual ASMS Conference on Mass Spectrometry and Allied Topics; 2001; Chicago, IL.
34. Alexander-Miller MA, Leggatt GR, Berzofsky JA. Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. Proc Natl Acad Sci U S A. 1996;93:4102-4107.
35. Yee C, Savage PA, Lee PP, Davis MM, Greenberg PD. Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers. J Immunol. 1999;162:2227-2234.
36. Molldrem JJ, Lee PP, Wang C, Champlin RE, Davis MM. A PR1-human leukocyte antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myelogenous leukemia. Cancer Res. 1999;59:2675-2681.
37. Christou M, Savas U, Schroeder S, et al. Cytochromes CYP1A1 and CYP1B1 in the rat mammary gland: cell-specific expression and regulation by polycyclic aromatic hydrocarbons and hormones. Mol Cell Endocrinol. 1995;115:41-50.
38. Liehr JG. Is estradiol a genotoxic mutagenic carcinogen? Endocrinol Rev. 2000;21:40-54.
39. Hudson CE, Schulte BA, Sutter TR, Norris JS. Steroid hormones modulate expression of cytochrome P450 enzymes in male hamster reproductive tract and leiomyosarcomas. Carcinogenesis. 2001;22:763-770.
40. Liehr JG, Ricci MJ. 4-hydroxylation of estrogens as marker of human mammary tumors. Proc Natl Acad Sci U S A. 1996;93:3294-3296.
41. Buters JT, Sakai S, Richter T, et al. Cytochrome P450 CYP1B1 determines susceptibility to 7, 12-dimethylbenz[a]anthracene-induced lymphomas. Proc Natl Acad Sci U S A. 1999;96:1977-1982.
42. Anderson KS, Urban R, Ryan D, et al. A phase I DNA vaccination trial of Zyc300: targeting the tumor antigen Cyp1B1. Keystone Symposia, Aspects of Tumor Immunology. Keystone, CO; 2003:401.
43. Chen YT, Scanlan MJ, Sahin U, et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci U S A. 1997;94:1914-1918.
44. Stanislawski T, Voss RH, Lotz C, et al. Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer. Nat Immunol. 2001;2:962-970.
45. Kao H, Marto JA, Hoffmann TK, et al. Identification of cyclin b1 as a shared human epithelial tumor-associated antigen recognized by T Cells. J Exp Med. 2001;194:1313-1324.